HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma
复制标题
DOI：
10.1016/s0046-8177(00)80195-1
复制
发表时间：
2000-01-01
期刊：
影响因子：
3.3
通讯作者：
Ross, JS
中科院分区：
文献类型：
--
作者：
Brien, TP;Odze, RD;Ross, JS
HER-2/neu 癌基因定位于染色体 17q，与表皮生长因子受体具有显着的同源性。 HER-2/neu 蛋白过度表达与多种肿瘤的不良预后相关，但其在巴雷特食管相关腺癌 (BEAd) 中的意义尚不清楚。因此，本研究的目的是通过荧光原位杂交（FISH）评估 63 例 BEAd 中 HER-2/neu 基因扩增的患病率和预后价值。使用 Ventana 独特序列探针（Ventana Medical Systems, Inc, Tuscon, AZ），通过 FISH 对 63 名 BEAd 患者（M/F 比率，10:1；平均年龄，63 岁）切除标本的常规处理组织切片进行 HER-2/neu 基因扩增。 FISH 结果与肿瘤的病理特征和患者的生存率相关。 54 名患者获得了临床随访数据（平均随访时间为 31 个月[范围为 1 至 152 个月]）。 63 例中有 12 例 (19%) HER-2/neu 基因被扩增。 HER-2/neu 基因扩增的存在显示出与肿瘤浸润深度 (P = .07)、淋巴结转移 (P = .13) 和病理分期 (P = .14) 相关的趋势，但与任何其他病理特征（例如分化程度或肿瘤大小）不相关。在单变量和多变量分析中，HER-2/neu 基因扩增与生存期缩短相关 (P = 0.03)。 FISH 测定的 HER-2/neu 癌基因扩增与患者生存期缩短相关，并独立预测 BEAd 患者的不良预后。嗡嗡声 31:35-39。版权所有 (C) 2000 W.B.桑德斯公司。
The HER-2/neu oncogene is localized to chromosome 17q and shares significant homology with the epidermal growth factor receptor. HER-2/neu protein overexpression has been associated with poor prognosis in a variety of tumors, but its significance in Barrett's esophagus-associated adenocarcinoma (BEAd) is unknown. Therefore, the aim of this study was to evaluate the prevalence and prognostic value of HER-2/neu gene amplification by fluorescence in situ hybridization (FISH) in 63 cases of BEAd. Routinely processed tissue sections from resection specimens of 63 patients with BEAd (M/F ratio, 10:1; mean age, 63 years) were assayed for HER-2/neu gene amplification by FISH using the Ventana unique sequence probe (Ventana Medical Systems, Inc, Tuscon, AZ). FISH results were correlated with the pathological features of the tumors and with patient survival. Clinical follow-up data were available for 54 patients (mean follow-up, 31 months [range, 1 to 152 months]). The HER-2/neu gene was amplified in 12 of 63 (19%) cases. The presence of HER-2/neu gene amplification showed a trend toward a correlation with depth of tumor invasion (P=.07), lymph node metastasis (P =.13), and pathological stage (P =.14), but did not correlate with any of the other pathological features, such as degree of differentiation or tumor size. On both univariate and multivariate analysis, HER-2/neu gene amplification was associated with shortened survival (P =.03). HER-2/neu oncogene amplification, as determined by FISH, correlates with shortened patient survival and independently predicts poor outcome in patients with BEAd. HUM PATHOL 31:35-39. Copyright (C) 2000 by W.B. Saunders Company.